Kailera Therapeutics (NASDAQ:KLRA) Stock Price Up 8.3% – Here’s Why

Kailera Therapeutics, Inc. (NASDAQ:KLRA) shares were up 8.3% during trading on Tuesday. The company traded as high as $12.51 and last traded at $12.38. 239,776 shares traded hands during trading, a decline of 72% from the average session volume of 869,952 shares. The stock had previously closed at $11.43.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Kailera Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Price Performance

The stock has a fifty day moving average of $14.18. The company has a market cap of $1.68 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). Equities research analysts forecast that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Trading of Kailera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KLRA. Tidal Investments LLC purchased a new position in Kailera Therapeutics in the 2nd quarter worth about $309,000. Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics during the second quarter worth $993,000. Mirador Capital Partners LP acquired a new stake in Kailera Therapeutics during the third quarter worth about $666,000. State Street Corp purchased a new stake in shares of Kailera Therapeutics during the 2nd quarter worth about $19,126,000. Finally, Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics during the second quarter worth approximately $24,233,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.